Catalog No.
Product Name
Application
Product Information
Citations
-
Aldose Reductase Inhibitor
Aldose reductase-IN-6 is a competitive inhibitor of aldose reductase (AR) with an IC50 of 3.164 μM and a Ki value of 0.018 μM. This compound demonstrates effective inhibition without cytotoxic effects on healthy cells, making it a valuable tool for investigating the role of aldose reductase in various biological processes. It is particularly relevant in studies related to diabetic complications and oxidative stress. -
Aldose Reductase Inhibitor
SG-210 is a selective aldose reductase (AR) inhibitor exhibiting potency with IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. By inhibiting aldose reductase, SG-210 effectively reduces sorbitol accumulation, which is beneficial in mitigating complications associated with diabetes, such as neuropathy and retinopathy, in streptozotocin-induced diabetic models. This compound serves as a valuable tool for research into diabetes-related pathologies and the mechanisms underlying metabolic disorders. -
Aldose Reductase 2 Inhibitor
ALR2-IN-10 is an inhibitor of Aldose Reductase 2, exhibiting a modest inhibition rate of 6% at a concentration of 27 μM. This compound is relevant for research related to diabetic complications, providing insights into the pharmacological modulation of glucose metabolism and related pathways. Suitable for studies exploring the therapeutic potential of targeting aldose reductase in diabetes-related tissue damage. -
Aldose Reductase Inhibitor
AD-5467 is a potent and selective inhibitor of aldose reductase, an enzyme involved in glucose metabolism. This compound exhibits significant antidiabetic effects, making it a valuable tool for research in metabolic diseases, particularly diabetes. Its selective inhibition of aldose reductase may aid in understanding the role of this enzyme in diabetic complications and the underlying mechanisms of glucose toxicity. -
Aldose Reductase Inhibitor
Salfredin A3 is an inhibitor of aldose reductase, a key enzyme involved in the polyol pathway. This compound exhibits significant biological activity by reducing the conversion of glucose into sorbitol, thereby mitigating osmotic and oxidative stress in various tissue types. Salfredin A3 is valuable in research applications focusing on diabetic complications and other conditions associated with aldose reductase overactivity. -
Aldose Reductase Inhibitor
Salfredin C2 is an aldose reductase inhibitor that effectively modulates glucose metabolism by inhibiting the conversion of glucose to sorbitol. This compound demonstrates significant biological activity in the treatment of diabetic complications and related conditions. It is particularly useful in research exploring diabetic neuropathy, retinopathy, and nephropathy, highlighting its potential as a therapeutic agent in metabolic disorders. -
Aldose Reductase Inhibitor
Salfredin C1 is an aldose reductase inhibitor that modulates the activity of this enzyme, which plays a crucial role in the polyol pathway. By inhibiting aldose reductase, Salfredin C1 may help mitigate complications associated with hyperglycemia, such as diabetic neuropathy and cataract formation. This reagent is suited for research applications aimed at understanding diabetes-related conditions and developing therapeutic strategies to manage these complications. -
Aldose Reductase Inhibitor
Salfredin C3 is a selective aldose reductase inhibitor that effectively modulates the polyol pathway. By inhibiting aldose reductase, it reduces the conversion of glucose to sorbitol, which plays a critical role in diabetic complications. This compound is valuable in research applications focused on diabetes-related disorders and oxidative stress pathways. -
Aldose Reductase Inhibitor
Salfredin A4 is an aldose reductase inhibitor that selectively modulates the enzyme's activity, impacting glucose metabolism. By inhibiting aldose reductase, it may help reduce sorbitol accumulation, which is relevant in diabetic complications. This compound is primarily utilized in research applications aimed at understanding diabetes-related pathways and the development of neuromodulatory therapies. -
Aldose Reductase Inhibitor
Floramanoside C is a potent aldose reductase inhibitor that demonstrates significant antioxidant activity by scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals. This compound is of particular interest in research related to diabetic complications and oxidative stress due to its ability to modulate carbohydrate metabolism. Floramanoside C can be utilized in studies exploring therapeutic options for managing conditions associated with elevated aldose reductase activity. -
Aldose Reductase Inhibitors
4′-Hydroxyflavone is a potent inhibitor of aldose reductase, demonstrating an IC50 value of 12 μM. This compound is significant in the study of diabetic complications and oxidative stress, as it can modulate glucose metabolism pathways. Its inhibition of aldose reductase makes it valuable for research applications focused on metabolic diseases and related therapeutic developments. -
Aldose Reductase Inhibitor
WF-3681 is a selective aldose reductase inhibitor, derived from fungal metabolites. This compound effectively inhibits the enzyme aldose reductase, which plays a crucial role in the polyol pathway, leading to the conversion of glucose to sorbitol. WF-3681 has strong potential in research applications related to diabetes complications and associated metabolic disorders, where oxidative stress and sorbitol accumulation are involved. -
Aldose Reductase Inhibitor
Salfredin B11 is an aldose reductase inhibitor that effectively modulates glucose metabolism by reducing the conversion of glucose to sorbitol. This compound exhibits significant biological activity in the context of diabetic complications, particularly in preventing neuropathy and retinopathy. Salfredin B11 is a valuable tool for research applications focused on the treatment of diabetes-related disorders and the study of oxidative stress responses. -
Aldose Reductase Inhibitor
2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole is an aldose reductase (ALR2) inhibitor, demonstrating significant biological activity in modulating glucose metabolism and potentially mitigating diabetic complications. This compound has also shown efficacy in inhibiting larval settlement in marine invertebrates, including barnacles, bryozoans, and polychaetes, while maintaining low toxicity. Its unique properties make it a valuable reagent for research in both diabetes and ecological studies. -
Aldose Reductase Inhibitor
Alrestatin sodium is an aldose reductase inhibitor that plays a significant role in modulating hyperglycemic conditions associated with diabetes mellitus. By inhibiting this enzyme, Alrestatin sodium helps to alleviate oxidative stress and cellular damage, contributing to the prevention of diabetic complications such as neuropathy. This compound is primarily utilized in research focused on diabetes-related pathologies and the development of therapeutic strategies. -
Aldose Reductase Inhibitor
MK181 is an aldose reductase (AR) inhibitor, demonstrating IC50 values of 0.71 μM for aldose reductase and 4.5 μM for AKR1B10. This compound engages the external loop A subpocket of AKR1B10, providing a targeted approach to modulating enzyme activity. MK181 is primarily utilized in research exploring diabetic complications and oxidative stress pathways, making it a valuable tool in pharmacological studies related to metabolic disorders. -
Aldose Reductase Inhibitor
MK 319 is a selective inhibitor of aldose reductase (AR) with an IC50 value of 0.3 μM. This compound is of particular interest in diabetes research, where it may be used to investigate pathways associated with diabetic complications. Additionally, MK 319's role in modulating glucose metabolism can provide insights into therapeutic strategies for managing diabetes and its related disorders. -
Aldose Reductase Inhibitor
Carboxy finasteride is a significant metabolite of the 5α-reductase inhibitor finasteride, targeting aldose reductase. As a biotransformation product of finasteride, it is primarily formed through oxidation by cytochrome P450 (CYP3A4) and represents the predominant metabolite found in urine, while hydroxy finasteride is more prevalent in plasma. This compound plays a crucial role in research related to metabolic pathways and the pharmacokinetics of finasteride, contributing to studies on diabetic complications and related enzymatic activities. -
Aldose Reductase Inhibitor
M79175 is an aldose reductase inhibitor that plays a crucial role in the management of diabetic complications. By inhibiting the enzyme, M79175 assists in the reduction of sorbitol accumulation, which is implicated in the pathogenesis of diabetic retinopathy. This reagent is relevant for researchers investigating early stages of diabetic retinopathy and potential therapeutic strategies for diabetes-related ocular disorders. -
Aldose Reductase Inhibitor
AL-4114 is a potent aldose reductase inhibitor that plays a critical role in the management of diabetic complications. This compound has demonstrated significant biological activity in the prevention of diabetic cataractogenesis, making it valuable for research focused on diabetes-related ocular disorders. Its application extends to the investigation of metabolic pathways and the development of therapeutic strategies for diabetes management. -
Aldose Reductase Inhibitor
ALO1567 is an orally available aldose reductase inhibitor that demonstrates an IC50 of 27 nM against rat lens aldose reductase. This compound is utilized in research focused on diabetes, particularly in studying the pathways related to hyperglycemia and osmotic stress in diabetic complications. Its specific targeting of aldose reductase makes it a valuable tool for investigating therapeutic strategies in metabolic disorders. -
Aldose Reductase Inhibitor
Salfredin A7 is an aldose reductase inhibitor that targets the enzyme responsible for converting glucose into sorbitol. This activity is significant in the context of diabetic complications, where the accumulation of sorbitol leads to cellular damage. Salfredin A7 exhibits anti-inflammatory properties and has potential applications in research focusing on diabetes-related pathologies and oxidative stress. Its inhibitory action on aldose reductase makes it a valuable reagent for studies investigating metabolic diseases and their associated complications. -
Glutamine Synthetase Inhibitor
JFD01307SC is a selective inhibitor of glutamine synthetase, which plays a crucial role in the conversion of L-glutamate to glutamine. By mimicking L-glutamate, JFD01307SC effectively targets and modulates the enzymes involved in glutamine biosynthesis. This compound is primarily utilized in research related to tuberculosis and other metabolic disorders, providing valuable insights into the therapeutic potential of glutamine metabolism modulation. -
cACE/NEP Inhibitor
AD012 is a dual inhibitor of the enzymes neprilysin (NEP) and angiotensin-converting enzyme (cACE). Designed from the C-domain selective ACE inhibitor, lisinopril-tryptophan, AD012 demonstrates significant antihypertensive and cardioprotective properties. This compound is valuable for research in cardiovascular health and the treatment of hypertension. -
NEP Inhibitor
GW 796406 is a potent neprilysin (NEP) inhibitor with an IC50 value of approximately 1.1-2.5 nM, exhibiting a higher selectivity compared to ACE, which has an IC50 of around 1.6-4.7 nM. This compound is valuable for exploring mechanisms involved in cardiovascular diseases and may aid in the development of therapeutics targeting NEP-related pathways. GW 796406's specificity and efficacy make it a useful tool for researchers studying cardiovascular health and related disorders. -
ACE/NEP Inhibitor
RB-105 is a potent dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), with Ki values of 4.2 nM and 1.7 nM, respectively. By inhibiting ACE, RB-105 decreases angiotensin II production and enhances bradykinin levels, while NEP inhibition further elevates natriuretic peptide levels, resulting in a synergistic increase in bradykinin. This compound exhibits significant antihypertensive and natriuretic effects in both spontaneously hypertensive and normotensive rat models, making RB-105 a valuable reagent for studies on hypertension and related cardiovascular conditions. -
NEP/ACE Inhibitor
Aladotril, a dual inhibitor of neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), exhibits potential in ameliorating cardiac hypertrophy without reducing blood pressure. This compound is valuable for research focused on heart failure and the mechanisms of cardiac remodeling following myocardial infarction. Its unique properties make it an important tool for studying cardiovascular health and therapeutic interventions. -
ACE/ECE-1/NEP Inhibitor
CGS 35601 is a potent inhibitor of endothelin-converting enzyme-1 (ECE-1), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE), exhibiting IC50 values of 55 nM, 2 nM, and 22 nM, respectively. This compound effectively suppresses pressor responses induced by big endothelin-1 and angiotensin I, while simultaneously enhancing the circulation of atrial natriuretic peptide (ANP). CGS 35601 serves as a valuable tool in cardiovascular research, particularly in delineating the regulatory mechanisms of cardiovascular function in animal models. -
Angiotensin-Converting Enzyme/Neprilysin Inhibitor
Alatrioprilat is an orally active inhibitor of angiotensin-converting enzyme (ACE) and neprilysin, with an IC50 of 19.6 nM for ACE and 6.1 nM for neprilysin. This compound is significant in the metabolism of hormonal peptides, particularly in the degradation of nitric oxide and atrial natriuretic factor (ANF). Alatrioprilat is applicable in cardiovascular disease research, offering insights into therapeutic strategies for conditions influenced by these pathways. -
p32-kinase activator
D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator. -
Thrombin inhibitor
Ximelagatran is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. -
HIV protease inhibitor
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. -
Caspase-6 inhibitor
Z-VEID-FMK is the specific recognition sequence for caspase-6/Mch2. Z-VEID-FMK is a synthetic peptide that irreversibly inhibits activity of VEID-dependent caspases (e.g., caspase-6). The inhibitor is designed as a methyl ester to facilitate cell permeability. -
Caspase-2 inhibitor
Z-VDVAD-FMK is a cell-permeable, irreversible inhibitor of caspase-2. Caspase inhibitors play an important role in investigating biological processes. -
PPP1R15A inhibitor
Sephin1 is a selective inhibitor of stress-induced PPP1R15A and targets disease associated with accumulation of misfolded protein. -
SHIP1 Inhibitor
3AC is a cell-permeable, selective inhibitor of SHIP1 polyphosphatase activity toward PIP3 (IC50 = 10 μM), but has no effect on SHIP2 or PTEN activity on PIP3. -
MMP inhibitor
4-epi-Chlortetracycline Hydrochloride is a tetracycline derivative that acts as a metalloproteinase (MMP) inhibitor, used in treating tissue destructive diseases and cancer -
DHODH inhibitor
Vidofludimus is a novel orally active and potent DHODH inhibitor. - Prodipine, a diphenyl-phosphonate derivative. The IC50s of Prodipine for purified and plasma Dipeptidyl peptidase IV (DPP IV) from the rabbit are 4.5 μM and 30 μM, respectively.
-
PP1 inhibitor
Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells. -
HCV Polymerase Inhibitor
Setrobuvir (ANA-598) is a direct-acting antiviral or DAA, is a non-nucleoside inhibitor of the HCV RNA polymerase
